Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical minoxidil + spironolactone + azelaic acid versus minoxidil alone for androgenetic alopecia
IRCT20200115046143N3Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of minoxidil, spironolactone and Azelaic acid in androgenetic alopecia (AGA) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Incidence and severity of androgenetic alopecia. Started Oct 2025; status: completed.
02
Drugs
minoxidilspironolactoneAzelaic acid
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on IRCT20200115046143N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200115046143N3.